Drugs / CTM-N2D
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05302037 | Nov 2024 → Nov 2025 overdue | cancer | CytoMed Therapeutics Pte Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT04107142 | Dec 2019 → Sep 2020 | colorectal cancer, gastric cancer, nasopharyngeal carcinoma, prostate cancer +2 | CytoMed Therapeutics Pte Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTM-N2D | “Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)” NCT04107142 ↗ |
| Action | Deplete | “The modified cells, which are readministered to the patient, have enhanced abilities to target and destroy cancers than unmodified immune cells.” NCT05302037 ↗ |
| Modality | Cell therapy | “Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells” NCT04107142 ↗ |
| Route | Intravenous | “Trial subjects will receive CTM-N2D by i.v infusion.” NCT05302037 ↗ |